Abstract:RationaleProteomics and metabolomics are widely used in the study of diabetes, but rarely in prediabetes research. This study aimed to explore the mechanisms of early-onset type 2 diabetes mellitus (T2DM) by analyzing proteomic changes at different stages of glucose metabolism. MethodsA total of 40 individuals undergoing routine physical health examinations between December 2016 and April 2017 were enrolled. Subjects were divided into four groups based on fasting blood glucose (FPG) levels: FPG < 5.6 mmol/L (group A); FPG >= 5.6 mmol/L and <6.1 mmol/L (group B); FPG >= 6.1 mmol/L and <7.0 mmol/L (group C); and FPG >= 7.0 mmol/L (group D). Each group had 10 cases. Sera from these 40 subjects were analyzed by label-free quantitative liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS). LC/MS/MS with selected reaction monitoring mode was also performed for qualitative and quantitative metabolomics analysis. Differentially expressed proteins were identified. Partial least squares discriminant analysis (PLS-DA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were used to analyze the differentially expressed metabolites. ResultsA total of 202 differentially expressed proteins were screened and were identified as mainly secreted proteins. Comparing group A with group B, 32 proteins were up-regulated and 18 proteins were down-regulated. Comparing group A with group C, 24 proteins were up-regulated and 24 proteins were down-regulated. Comparing group A with group D, 19 proteins were up-regulated and 17 proteins were down-regulated. The fold change for up-regulated proteins was >1.2, p < 0.05, while the fold change for down-regulated proteins was <-1.2, p < 0.05. PLS-DA and OPLS-DA revealed 113 differentially expressed metabolites. Correlation analysis of differentially expressed metabolites of group A versus group B revealed that among the down-regulated differential proteins, transforming growth factor beta-induced protein ig-h3 correlated negatively with metabolite L-saccharin, while among the up-regulated differential proteins, apolipoprotein C-IV correlated negatively with metabolite 3-methyloxindole. Among all differentially expressed proteins, 19 proteins were associated with early initiation of chronic inflammation, including CD14 and CSF-1R, which were newly identified in the early onset of T2DM. ConclusionsMany proteins are differentially expressed between prediabetes and after T2DM diagnosis, although the specific mechanism remains unclear. The expression level of CD14 was significantly up-regulated and that of CSF-1R was significantly down-regulated when FPG was >= 5.6 mmol/L, suggesting that CD14 and CSF-1R may be important markers for early-onset T2DM and may serve as new targets for T2DM treatment.

Characterization of Post‐Translational Modifications Related to Cardiovascular Disease

Analysis of Protein Expression Changes in Patients with Prediabetes Using Proteomics Approaches.

Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease

Biomarker identification and risk assessment of cardiovascular disease based on untargeted metabolomics and machine learning

1799-LB: Identification of Proteomics Signature for Vascular Complications in Type 2 Diabetes

Vascular Proteomics: Linking Proteomic and Metabolomic Changes

Identification of potential biomarkers for diabetic cardiomyopathy using LC-MS-based metabolomics

Heart Disease, Clinical Proteomics and Mass Spectrometry

Development and Validation of a Sensitive and Reliable Targeted Metabolomics Method for the Quantification of Cardiovascular Disease-Related Biomarkers in Plasma Using Ultrahigh-Performance Liquid Chromatography-Tandem Mass Spectrometry

Research progress on post-translational modification of proteins and cardiovascular diseases

Abstract 14120: Proteomics of Diabetes-Related Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study

Vascular proteomics: linking proteomic and metabolomic changes.

Changes of Myocardial Lipidomics Profiling in a Rat Model of Diabetic Cardiomyopathy Using UPLC/Q-TOF/MS Analysis

Metabolic and Proteomic Profiling of Coronary Microvascular Dysfunction: Insights from Rat Models

Dietary metabolic signatures and cardiometabolic risk

Proteomic profiling for detection of early-stage heart failure in the community

Integrated Glycoprotein Immobilization Method for Glycopeptide and Glycan Analysis of Cardiac Hypertrophy.

Proteomic Profiling of Early-Stage Heart Failure Identifies Candidate Biomarkers and Molecular Pathways of Cardiac Inflammation in the Project Baseline Health Study

Non-invasive monitoring and classification of coronary heart disease by metabolomics and lipidomics

A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia